Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma

Inclusion Criteria: * Patients with advanced solid tumors or relapses/refractory non-Hodgkin's lymphoma confirmed by histology or cytology * Has at least one measurable lesion (solid tumor according to RECIST v1.1 criteria, non-Hodgkin's lymphoma according to Lugnao criteria) * ECOG score of 0 or 1; * Expected survival time ≥ 3 months (at the discretion of the investigator); * Adequate organ and bone marrow function; * Voluntarily sign the informed consent form; Exclusion Criteria: * Has central nervous system primary malignant tumor, active epileptic seizure, spinal cord compression or carcinomatous meningitis * The previous anti-tumor treatment has not passed the prescribed washout period * HIV antibody is positive, or with other acquired/congenital immunodeficiency disease, or with history of organ transplantation; * Active hepatitis B or hepatitis C virus (HCV) antibody was positive; * Patients who are pregnant or lactating; * Known or suspected hypersensitivity to the study drug or its pharmaceutical excipients (including mono-hydrate citric acid, sodium di-hydrate citric acid, mannitol, polysorbate, arginine, succinic acid); * Any active autoimmune disease, or known history of autoimmune disease, or syndrome requiring systemic steroids or immunosuppressive medications (other than controlled thyroid disease with alternative therapy/non-immunosuppressive therapy); * Participation in another therapeutic or interventional clinical study in the meantime; * Other circumstances where the investigator considers it is not appropriate to participate in the study.